FDA Considers Pembrolizumab/Chemotherapy for Approval in Advanced Gastric/GEJ Cancer
April 13th 2023KEYNOTE-859 findings are under review by the FDA as the regulatory body considers an approval application for pembrolizumab plus chemotherapy for the treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
FDA Halts Phase 1 Study MT-0169 Due to Unacceptable Toxicity
April 12th 2023Multiple cases of unacceptable toxicity requiring dose reductions have occurred in a phase 1 study of MT-0169 in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The FDA has placed a partial clinical hold on the study
Room to Grow in the Small Cell Lung Cancer Treatment Landscape
April 10th 2023In an interview with Targeted Oncology, Nitika Sharma, MD, discussed frontline treatment options for small cell lung cancer and data supporting their use. Sharma also discussed ongoing clinical trials that may bring new therapies in the near future.
Dostarlimab Plus Chemo Designated SOC for Primary Advanced/Recurrent Endometrial Cancer
April 7th 2023The addition of dostarlimab to standard combination chemotherapy in the phase 3 RUBY study showed a significant survival improvement in patients with primary advanced or recurrent endometrial cancer.
Doublet and Triplet Combinations Continue to Challenge Monotherapy in Advanced RCC
April 6th 2023In an interview with Targeted Oncology™, Yousef Zakharia, MD discussed evidence supporting both doublet and triplet therapy for the treatment of previously untreated, advanced/metastatic renal cell carcinoma.
Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations
April 5th 2023In the phase 3 DUO-O study, combing 5 targeted and chemotherapy agents for the treatment of newly diagnosed, advanced, high-grade epithelial ovarian cancer with or without BRCA mutations has shown to extend progression-free survival.
Ficlatuzumab With Cetuximab Achieves PFS Benefit in Recurrent/Metastatic HNSCC
April 5th 2023HGF and c-MET inhibition with ficlatuzumab and cetuximab showed progression-free survival benefit in patients with pan-refractory recurrent or metastatic head and neck squamous cell carcinoma, according to phase 2 study data.
Expert Marks Anti-VISTA/Anti-PD-1 Therapies as a Potential New Strategy for Advanced Solid Tumors
March 20th 2023Anti-VISTA therapy may be the therapy type to be used with PD-1/PD-L1 inhibitors to treat patients with advanced solid tumors, expert say. One agent, KVA12123, has just entered phase 1 clinical research.
Enzalutamide/Leuprolide Extends MFS in nmHSPC With High-Risk Bochemical Recurrence
March 17th 2023The phase 3 EMBARK trial of enzalutamide plus leuprolide is the first to elicit a statistically significant improvement in metastasis-free survival in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade Glioma
March 16th 2023Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.